131 related articles for article (PubMed ID: 1760859)
1. Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.
Nagel JD; Krüger I; Ghussen F; Bode U
Cancer Chemother Pharmacol; 1991; 29(2):155-8. PubMed ID: 1760859
[TBL] [Abstract][Full Text] [Related]
2. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
[TBL] [Abstract][Full Text] [Related]
3. Systemic effects of hyperthermic isolated lower limb perfusion with carboplatin and interferon-beta.
Tominaga R; Nakano T; Shibata S; Siraishi K; Nagae S; Nakayama J; Yasui H
Artif Organs; 2001 Jan; 25(1):36-41. PubMed ID: 11167557
[TBL] [Abstract][Full Text] [Related]
4. Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
Huber R; Krüger I; Kuper K; Huber PM; Pichlmaier H
Am J Surg; 1995 Oct; 170(4):345-52. PubMed ID: 7573726
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer.
Nicoletto MO; Padrini R; Galeotti F; Ferrazzi E; Cartei G; Riddi F; Palumbo M; De Paoli M; Corsini A
Cancer Chemother Pharmacol; 2000; 45(6):457-62. PubMed ID: 10854132
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
8. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon.
Nakayama J; Takeuchi M; Mayumi H; Nagae S; Matsuda K; Yasui H; Takahashi S; Hori Y
J Dermatol; 1996 Jan; 23(1):6-15. PubMed ID: 8720252
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic isolated limb perfusion with intra-arterial administration of carboplatin and/or interferon-beta for the treatment of malignant melanoma of the leg.
Nakayama J; Takeuchi M; Mayumi H; Nagae S; Matsuda K; Yasui H; Takahashi S; Hori Y
J Dermatol; 1994 Nov; 21(11):915-22. PubMed ID: 7852655
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.
Nagel JD; Varossieau FJ; Dubbelman R; ten Bokkel Huinink WW; McVie JG
Cancer Chemother Pharmacol; 1992; 29(6):480-4. PubMed ID: 1568292
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of dacarbazine in the regional perfusion of extremities with melanoma.
Didolkar MS; Jackson AJ; Lesko LJ; Fitzpatrick JL; Buda BS; Johnston GS; Zech LA
J Surg Oncol; 1996 Nov; 63(3):148-58. PubMed ID: 8944058
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb.
Skene AI; Bulman AS; Williams TR; Thomas JM; Westbury G
Br J Surg; 1990 Jul; 77(7):765-7. PubMed ID: 2383752
[TBL] [Abstract][Full Text] [Related]
14. [Technique and results of hyperthermic perfusion of the extremity in melanoma patients].
Omlor G; Bahmer F; Meessen S; Zang D; Feifel G; Zaun H
Langenbecks Arch Chir; 1993; 378(1):21-5. PubMed ID: 8437498
[TBL] [Abstract][Full Text] [Related]
15. Desflurane as a marker of limb-to-systemic leak during hyperthermic isolated limb perfusion.
Stanley G; Sundarakumaran R; Crowley R; Kavanah M
Anesthesiology; 2000 Aug; 93(2):574-6. PubMed ID: 10910485
[No Abstract] [Full Text] [Related]
16. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Schleyer E; Kamischke A; Kaufmann CC; Unterhalt M; Hiddemann W
Leukemia; 1994 Mar; 8(3):435-40. PubMed ID: 8127148
[TBL] [Abstract][Full Text] [Related]
17. Current techniques of hyperthermic isolated limb perfusion for malignant melanoma.
Tominaga R; Kohno H; Mayumi H; Shiraishi K; Nagae S; Nakayama J; Yasui H
Surg Today; 2000; 30(4):339-42. PubMed ID: 10795866
[TBL] [Abstract][Full Text] [Related]
18. [Cardiocirculatory side effects of hyperthermic extremity perfusion].
Omlor G; Molter G; Meessen S; Gross G; Seyfert U; Feifel G
Langenbecks Arch Chir; 1993; 378(1):17-20. PubMed ID: 8437497
[TBL] [Abstract][Full Text] [Related]
19. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
[TBL] [Abstract][Full Text] [Related]
20. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
